Search Results
Your search for The matches 34701 pages
Showing 16201 - 16250Leaders of Harborside Medical Education Recognized by the Alliance for Continuing Education in the Health Professions
THE PRINCIPALS and staff of Harborside, publisher of The ASCO Post, congratulate Harborside Medical Education (HSME) for staff recognition by the Alliance for Continuing Education (CE) in the Health Professions (the Alliance). Two senior staff were honored during the awards ceremony preceding the...
Opioid Use Following Thoracoscopic Surgery in Early-Stage Lung Cancer
In a study reported in a research letter in JAMA Oncology, Stephanie Tuminello, MPH, and colleagues found that video-assisted thoracoscopic surgery (VATS) was less likely than open resection to be associated with long-term opioid use in patients undergoing surgery for early-stage lung cancer....
In Vitro and Ex Vivo Activity of Gentian Violet in Cutaneous T-Cell Lymphoma
As reported in JAMA Dermatology, Jianqiang Wu, MD, PhD, and Gary S. Wood, MD, found that the widely available nonprescription topical antimicrobial agent gentian violet has potent activity against cutaneous T-cell lymphoma (CTCL) in studies in vitro and ex vivo. The study involved high-throughput ...
Neoadjuvant Combination Checkpoint Blockade in Advanced Melanoma
Neoadjuvant combination checkpoint blockade showed activity among patients with high-risk stage III melanoma in a small study. However, a high incidence of side effects caused the trial to be closed early. These results were published by Rodabe N. Amaria, MD, Assistant Professor of Melanoma...
Advancing the Science and Art of Integrative Oncology
In 2019, we will mark the 20th year of the establishment of the Integrative Medicine Service at Memorial Sloan Kettering Cancer Center (MSK), which helped lay the foundation for the emerging field of integrative oncology. Over the past 2 decades, academic cancer institutions, including The...
Breast Cancer Surgical Terminology Should Be Updated to Reflect Modern Medical Practice
BREAST CANCER is a microscopic disease, with most patients presenting with “localized” stage I to III disease, for which they are offered curative-intent surgery often accompanied by radiation therapy, chemotherapy, and hormonal therapy. More accurately, we now know that patients with localized...
Living My Best Life
Five years ago, I was living my dream life. I was under contract as a commentator on Fox News, which necessitated commuting weekly from my home in Los Angeles to New York, and was building a new home in Palm Springs with my partner, Matt Lashey. Not only was my career and personal life going well,...
Lorlatinib Shows Overall and Intracranial Activity in ALK-Positive NSCLC
IN A GLOBAL phase II study reported in The Lancet Oncology, Benjamin J. Solomon, MBBS, of Peter MacCallum Cancer Centre, Melbourne, and colleagues found that lorlatinib showed high overall and intracranial activity in patients with advanced ALK-positive non–small cell lung cancer (NSCLC) who were...
Direct-to-Consumer Genetic Test on Hereditary Colorectal Cancer Syndrome Receives FDA Clearance
ON JANUARY 22, 2019, 23andMe received U.S. Food and Drug Administration (FDA) clearance for a genetic health risk report on the hereditary colorectal cancer syndrome MUTYH-associated polyposis. The clearance follows the FDA’s authorization for 23andMe’s BRCA1/BRCA2 (Selected Variants) Genetic...
FDA Approves Ibrutinib in Combination With Obinutuzumab in Treatment-Naive CLL/SLL
ON JANUARY 28, 2019, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica), a Bruton’s tyrosine kinase inhibitor, in combination with obinutuzumab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This is the first approval of...
Encourage Lung Cancer Screening to Prevent Early Deaths
Discussions of benefits and harms from screening of high-risk populations for lung cancer have missed the point. The National Lung Screening Trial (NLST) showed an early and statistically significant major benefit in all-cause mortality from computed tomography (CT) screening.1 Those referred for...
How Turning ‘Cold’ Tumors Into ‘Hot’ Ones May Improve Response to Immunotherapy
The proliferation of immunotherapeutics in the treatment of cancer over the past decade has revolutionized the way many cancers are treated, especially lung cancer and melanoma, as well as some blood cancers, including leukemia and lymphoma, drastically improving outcomes for many patients with...
V. Craig Jordan, OBE, PhD, DSc, FMedSci, Receives Reynold Spector Award in Clinical Pharmacology
V. CRAIG JORDAN, OBE, PhD, DSc, FMedSci, of The University of Texas MD Anderson Cancer Center, will receive the 2019 Reynold Spector Award in Clinical Pharmacology, during the American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology 2019 in...
Julian Schink, MD, Named Chief Medical Officer of CTCA
JULIAN SCHINK, MD, has been appointed Chief Medical Officer of Cancer Treatment Centers of America (CTCA). As Chief Medical Officer for the comprehensive cancer care network, Dr. Schink will provide leadership and direction for its enterprise-wide clinical programs and will serve as a liaison...
Novel Treatments of Myelodysplastic Syndromes
AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on seven different studies on new therapeutics in myelodysplastic syndromes (MDS). Among the treatments highlighted here are the erythroid maturation...
NCCN Guidelines Exceed 10 Million Downloads in 2018
THE NATIONAL Comprehensive Cancer Network® (NCCN®) announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) were downloaded more than 10 million times in 2018, marking a 26% increase over downloads in 2017. The NCCN Guidelines provide up-to-date recommendations for...
Integrative Oncology Scholars Program: Model for Evidence-Based Complementary Care
THE FIRST full year of educational training in the practice of complementary therapies is now underway at the University of Michigan in Ann Arbor through its Integrative Oncology Scholars Program, which launched in 2017. The program, which is supported through a 5-year grant from the National...
FDA Pipeline: Treatments for Tenosynovial Giant Cell Tumor and Pancreatic Cancer, Plus a Statement on Breast Implant–Associated Lymphoma
The U.S. Food and Drug Administration (FDA) recently granted the following designations and applications and also issued a statement: Priority Review for Pexidartinib in Tenosynovial Giant Cell Tumor The FDA has accepted a new drug application (NDA) and granted Priority Review for pexidartinib...
Immunotherapy in Patients With HIV Infection and Advanced Cancer
A study published by Cook et al in JAMA Oncology focused on whether treatment with checkpoint inhibitors is both safe and effective in patients with advanced cancer who are also human immunodeficiency virus (HIV)-positive. Because checkpoint inhibitors manipulate the immune system, the concern has...
Do Certain Sedentary Behaviors Increase the Risk of Young-Onset Colorectal Cancer?
Although colorectal cancer rates in older adults have been decreasing in the United States since the mid-1980s, incidence rates for the cancer have been increasing among young and middle-aged adults, according to a study by the American Cancer Society (ACS). Based on the new data, in 2018, the ACS...
Multiethnic Cohort Study Update on Racial/Ethnic Differences in Lung Cancer Incidence
In an update from the Multiethnic Cohort Study reported in the Journal of the National Cancer Institute, Stram et al found persistent racial/ethnic differences in risk for lung cancer at similar levels of cigarette smoking intensity. A prior report from the study found that African Americans and...
More Than 60 Leading Health-Care Organizations Call on CMS to Maintain Coverage for Medically Necessary Cancer Testing
Leading health-care companies and organizations representing patients, providers, academic medical centers, laboratories, and diagnostic manufacturers urged the Centers for Medicare & Medicaid Services (CMS) to revise its interpretation of the National Coverage Determination (NCD) for...
Machine Learning Identifies Multiple Underlying Factors Predicting Response to Immunotherapy
A research team is using a branch of artificial intelligence known as machine learning to better target immunotherapy to those who will benefit. In a recent study published by Leiserson et al in PLOS One, the team used data from a clinical trial of patients with bladder cancer to...
Site of Care May Affect Racial and Ethnic Minorities’ Access to Palliative Treatment
For patients at the end of life, palliative care can prolong survival and improve the quality of life for patients with a life-threatening illness and for their families—but studies have found that racial and ethnic minorities are less likely to receive end-of-life palliative care than...
Postmastectomy Hypofractionated vs Conventionally Fractionated Radiotherapy for High-Risk Breast Cancer
In a Chinese, single-center, noninferiority phase III trial reported in The Lancet Oncology, Wang et al found that postmastectomy hypofractionated radiotherapy was noninferior to and associated with similar toxicities vs conventionally fractionated radiotherapy in patients with high-risk breast...
'Deep Learning'–Based Visual Evaluation for Cervical Cancer Screening
In an observational study reported in the Journal of the National Cancer Institute, Hu et al found that an automated 'deep learning'–based visual evaluation algorithm permitted identification of cervical precancer/cancer cases with greater accuracy than other screening methods. Study Details ...
FDA Approves Caplacizumab-yhdp for Acquired Thrombotic Thrombocytopenic Purpura
Today, the U.S. Food and Drug Administration approved caplacizumab-yhdp (Cablivi) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a...
Letter to the Editor: Survey on DOACs in Cancer-Related Venous Thromboembolism
This letter is a follow-up to a report published previously in The ASCO Post. Recent trials report comparable or improved efficacy of direct-acting oral coagulants (DOACs) over low–molecular-weight heparins (LMWH) in the treatment of cancer-related VTE (cVTE) at the expense of increased...
Real-World Treatment Impact of Newer Agents on Survival of Patients With Metastatic Melanoma
The approval of several new agents for metastatic melanoma in the past several years has led to changes in how the disease is treated and managed. Treatments such as the programmed cell death protein 1 (PD-1) inhibitors pembrolizumab, ipilimumab, and nivolumab; BRAF inhibitors; and MEK inhibitors...
Impact of Stereotactic Ablative Radiotherapy on Survival for Patients With Advanced Cancers
The first report from a phase II, multicenter clinical trial has found that a newer, more aggressive form of radiation therapy—stereotactic ablative radiation—can extend long-term survival for some patients with stage IV cancers, while maintaining their quality of life. The study was...
CYP2D6 Genotypes, Endoxifen Levels, and Clinical Outcome in Early-Stage Breast Cancer Treated With Adjuvant Tamoxifen
In a Dutch-Belgian study (CYPTAM) reported in the Journal of Clinical Oncology, Sanchez-Spitman et al found no associations between CYP2D6 genotypes or levels of endoxifen (active metabolite of tamoxifen) and clinical outcomes in patients receiving adjuvant tamoxifen for early-stage breast cancer....
Effect of Peer Review Within a Cancer Care Network on Use of Hypofractionated Radiotherapy for Early-Stage Breast Cancer
In a study reported in the Journal of Oncology Practice, Ganju et al found that implementation of a cancer care network–wide peer review process aimed at standardizing treatment resulted in increasing use of hypofractionated radiotherapy in early-stage breast cancer at community-based...
Avelumab in Recurrent or Refractory Ovarian Cancer
In phase Ib results from the JAVELIN Solid Tumor Trial reported in JAMA Oncology, Disis et al found that avelumab produced durable responses in some patients with recurrent or refractory ovarian cancer. In the study, an expansion cohort of 125 women with advanced disease who had received...
HLA Mismatch and Skin Cancer Risk After Organ Transplant
Data on the risk factors for the development of skin cancer after a solid organ transplant are limited. In a retrospective cohort study, researchers sought to determine the relationship between human leukocyte antigen (HLA) mismatch and risk of skin cancer after transplant. Their findings were...
American Lung Association's State of Tobacco Control Report Released
According to the American Lung Association’s recently released 2019 State of Tobacco Control report, states and the federal government have not taken meaningful action in establishing policies to prevent and reduce tobacco use, the nation's leading cause of preventable death and disease. ...
Clonal MET Amplification and Tyrosine Kinase Inhibitor Treatment Outcome in EGFR-Mutant NSCLC
In a Singaporean study reported in the Journal of Clinical Oncology, Lai et al found that tyrosine kinase inhibitor treatment outcome did not differ according to mesenchymal epithelial transition factor (MET)-high vs MET-low status in treatment-naive, EGFR-mutant non–small cell lung cancer...
Quality of Life in Men Living With Advanced and Localized Prostate Cancer
In a population-based study reported in The Lancet Oncology, Downing et al found little difference in health-related quality of life (HRQOL) between men with advanced vs localized prostate cancer. Sexual function problems were common among all patients—and often not addressed—and use of ...
Obesity-Related Cancers Rising in Young Adults in the United States
A new study has found rates are increasing for 6 of 12 cancers related to obesity in younger adults in the United States, with steeper increases in progressively younger ages and successively younger generations. The study, published by Sung et al in The Lancet Public Health, also looked at rates...
New Standards for Safe Handling of Hazardous Drugs Focus on Developing Evidence-Based Measures
ASCO recently published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology.1 ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is...
Taking a Stand: How ASCO Develops Policy Guidance and Position Statements
As a global thought leader in the spheres of cancer care and research, ASCO recognizes the importance of taking a position on certain key issues affecting its members and the patients they serve. As a result, ASCO will, on occasion, release policy guidance and position statements when existing...
New JOP Article Highlights Challenges Oncologists Face Due to a Lack of Interoperability, and How CancerLinQ® Can Help
A new article in the Journal of Oncology Practice (JOP)1 looks at how ASCO’s commitment to CancerLinQ® can lead to improvements in the interoperability of electronic health records (EHRs). The article, by Wendy S. Rubinstein, MD, PhD, FACP, FACMG, Deputy Medical Director of CancerLinQ LLC,...
New ASCO Answers Fact Sheet: When the Doctor Says ‘Cancer’
People diagnosed with cancer often say they were stunned when they heard the news of their diagnosis, and were unable to process what their health-care provider said afterward. Give your patients easy-to-understand information they can take home with them. When the Doctor Says “Cancer” is a 1-page...
Leave a Legacy of Hope
By including a planned gift to ASCO’s Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for patients with cancer years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and...
Clinical Cancer Advances 2019: ASCO Names Advance of the Year, Debuts Research Priorities for the Cancer Community
In the release of its annual report on progress against cancer, Clinical Cancer Advances 2019, ASCO recognized progress in treating rare cancers as the Advance of the Year. The report catalogs a year’s worth of remarkable research advancements, reinforces the need for continued federal research...
Expert Point of View: Steven Gore, MD, Eyten Stein, MD, and Elihu H. Estey, MD
In discussions after these presentations, several points were made by several experts. To begin, Steven Gore, MD, Director of Hematologic Malignancies at Yale Medical School, called the study of venetoclax plus 10-day decitabine “very important,” but he raised the issue of appropriate dosing. He...
Data Mount for Venetoclax as Add-on Therapy in Acute Myeloid Leukemia
The benefit of adding venetoclax to a hypomethylating agent or low-dose cytarabine in the front-line treatment of acute myeloid leukemia (AML) was evident from a number of studies reported at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition (see Table 1). For elderly...
Expert Point of View: Ravi Vij, MD and Saad Usmani, MD
Ravi Vij, MD, Professor of Medicine at Washington University School of Medicine, St. Louis, and Saad Usmani, MD, Director of Plasma Cell Disorders at Levine Cancer Institute, Charlotte, North Carolina, spoke to The ASCO Post about the studies presented on chimeric antigen receptor (CAR) T-cell...
Multiple Myeloma Pipeline Filled With CAR T-Cell Therapies
The burgeoning pipeline of chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) in multiple myeloma was on full display at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. A bispecific antibody also made its debut in this busy...
Expert Point of View: Mrinal S. Patnaik, MBBS and David P. Steensma, MD
Mrinal S. Patnaik, MBBS, Associate Professor of Internal Medicine and Oncology and a consultant in hematology at the Mayo Clinic, Rochester, commented on the MEDALIST trial for The ASCO Post. “Given its unique mode of action, relative ease of administration, and excellent tolerability,...
Luspatercept May Reduce the Need for Transfusion in Lower-Risk Myelodysplastic Syndromes
In the randomized, double-blind, phase III MEDALIST trial, the experimental drug luspatercept significantly reduced the need for frequent red blood cell transfusions in patients with lower-risk myelodysplastic syndromes (MDS) and ring sideroblasts. With luspatercept, 37.9% remained transfusion-free ...
